<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635256</url>
  </required_header>
  <id_info>
    <org_study_id>ZKS-121-003</org_study_id>
    <secondary_id>ARO-2016-5</secondary_id>
    <nct_id>NCT02635256</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiosurgery for Localised Prostate Cancer</brief_title>
  <acronym>HYPOSTAT</acronym>
  <official_title>Hypofractionated Radiosurgery for Localised Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saphir Radiosurgery Center Northern Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypofractionated radiosurgery has been investigated in a few trials and appears to be safe
      and feasible.

      Investigators initiated this multicenter phase II prospective trial to analyse feasibility
      (toxicity) of hypofractionated radiosurgery with 5 fractions in patients with localised
      prostate cancer, who are ineligible for the &quot;PREFERE trial&quot; under the hypothesis that the
      ratio of patients with late toxicity ≥ grade 2 after 1 year amounts 2,8% and is significant
      lower than 17.5%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental radiosurgery of prostate with 5 fractions each with 7,00 Gy (total application
      rate of 35,00 Gy).

      Planned visits are: Baseline, visits at every radiation day and four follow ups (4-6 weeks, 3
      months, 6 months and one year after last day of radiation).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late toxicity measured with Radiation Therapy Oncology Group-(RTOG)-Score</measure>
    <time_frame>12-15 months after radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports.</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA)</measure>
    <time_frame>At the time of inclusion and 1, 3, 6-9 and 12-15 months after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>Screening and 3, 6-9 and 12-15 months after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC Quality of Life Questionnaire (QLQ) C30</measure>
    <time_frame>At the time of inclusion and 12-15 months after radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Hypofractionated Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 fractions with 7 Gy, total dose 35 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Radiosurgery</intervention_name>
    <description>Image-guided stereotactic Linac based RT preferable with &quot;dedicated radiosurgery system&quot; such as CyberKnife</description>
    <arm_group_label>Hypofractionated Radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Localised, histopathologically confirmed Prostate Cancer (cT1-3 N0 M0)

          -  Gleason-grade ≤7

          -  Guideline-based staging

          -  Age ≥ 60 years

          -  PSA &lt; 15 ng/ml

          -  Volume of the prostate &lt;80 cm³

          -  IPSS-Score ≤12

          -  Written informed consent

        Exclusion Criteria:

          -  History of prior pelvic radiotherapy

          -  Contraindication to MRI or Fiducial marker implantation (e.g. allergy to gold),

          -  Immunosuppressive therapy

          -  Relevant comorbidity thought to adversely affect treatment compliance,

          -  Legal incapacity or lack of informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Dunst, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saphir Radiosurgery Center Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt, Department of Radiation Therapy and Oncology</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saphir Radiosurgery Center Northern Germany</name>
      <address>
        <city>Güstrow</city>
        <zip>18273</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Cyberknife Center Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Jiang P, Krockenberger K, Vonthein R, Tereszczuk J, Schreiber A, Liebau S, Huttenlocher S, Imhoff D, Balermpas P, Keller C, Dellas K, Baumann R, Rödel C, Hildebrandt G, Jünemann KP, Merseburger AS, Katz A, Ziegler A, Blanck O, Dunst J. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. Radiat Oncol. 2017 Aug 18;12(1):138. doi: 10.1186/s13014-017-0872-2.</citation>
    <PMID>28821268</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Juergen Dunst, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr. med. Juergen Dunst</investigator_title>
  </responsible_party>
  <keyword>hypofractionation</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

